S90652 in Paediatric Hypertension


The aim of the study is to assess the long-term safety and effects on blood pressure of a paediatric formulation of perindopril in hypertensive children

Full Title of Study: “Safety and Effects on Blood Pressure of Daily Dose 0.025 to 0.135 Milligram Per Kilogram of S90625 a Paediatric Formulation of Perindopril, in Hypertensive Children – 24 Months”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2010


  • Drug: Perindopril

Clinical Trial Outcome Measures

Primary Measures

  • Clinical safety assessed from the patient’s (parents) complaints and clinical follow-up

Secondary Measures

  • Blood pressure

Participating in This Clinical Trial

Inclusion Criteria

  • Hypertensive children, who have been treated for four months at least with S90652, with safety and efficacy Exclusion Criteria:

  • Poorly controlled hypertension – Girls with signs of pubescence

Gender Eligibility: All

Minimum Age: 30 Months

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Institut de Recherches Internationales Servier
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Patrick Niaudet, Pr, Study Chair, Hôpital Necker-Enfants Malades, Paris, France

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.